2026-01-13 - Analysis Report
**Company Overview**
Johnson & Johnson is a multinational health care products company.

**Return Rate Comparison**

* Cumulative return of review stock (JNJ): 54.09%
* Cumulative return of comparison stock (VOO (S&P 500)): 94.34%
* Divergence: -40.25% (simply the difference in cumulative return on the last day of the data)

**Alpha, Beta, and Market Capitalization Analysis**

| Period | CAGR | MDD | Alpha | Beta | Market Capitalization |
| --- | --- | --- | --- | --- | --- |
| 2016-2018 | 6.00% | 16.80% | 3.00% | 0.70 | 310.9B |
| 2017-2019 | 18.00% | 16.80% | 1.00% | 0.70 | 351.4B |
| 2018-2020 | 19.00% | 16.80% | -2.00% | 0.70 | 379.2B |
| 2019-2021 | 32.00% | 10.70% | -12.00% | 0.60 | 412.2B |
| 2020-2022 | 8.00% | 13.80% | 10.00% | 0.50 | 425.6B |
| 2021-2023 | -18.00% | 13.80% | -19.00% | 0.30 | 377.6B |
| 2022-2024 | -30.00% | 13.80% | -50.00% | 0.20 | 348.4B |
| 2023-2025 | 30.00% | 13.80% | -32.00% | 0.10 | 498.6B |

**Recent Stock Price Fluctuations**

* 5-day moving average (SMA): $206.43
* 20-day SMA: $207.69
* 60-day SMA: $200.29
* Close: $209.72
* Recent high fluctuation: 2.61 (sharp rebound)

**RSI, PPO Index, and Delta_Previous_Relative_Divergence Analysis**

| Indicator | Value |
| --- | --- |
| Market Risk Indicator (MRI) | 0.80 |
| RSI | 58.19 |
| PPO | -0.20 |
| Hybrid Signal: | Buy |
| Risk Level: | Medium |
| Recent (20 days) relative divergence change | -6.80 |
| 7-day Rank change | -3 |
| 7-day Dynamic Expected Return change | -22.70 |
* Expected Return: -74.90%
* Sharp rebound/decline: yes

**Recent News & Significant Events**

* [2026-01-12] Why Johnson & Johnson stock is up today: new Rybrevant data and earnings ahead
* [2025-12-19] Jim Cramer Couldn’t Stop Gushing About Johnson & Johnson (JNJ)’s Cancer Drugs
* [2026-01-12] Johnson & Johnson $JNJ Shares Sold by Atwater Malick LLC
* [2026-01-12] Assessing Johnson & Johnson (JNJ) Valuation After Drug Pricing Deal And New Clinical Trial Results
* [2025-12-30] More Upside For JNJ Stock In 2026?
* [2026-01-09] J&J Agreement Brings 15 of 17 Pharma Companies Into Trump's Drug-Pricing Effort

**Analyst Opinions**

* Analyst Consensus:
    - Key: Buy
    - Mean: 2.16 (Strong Buy ~ Buy)
    - Opinions: 24
    - Target Price (avg/high/low): 212.00 / 240.00 / 155.00

**Recent Earnings Analysis**

| Date | EPS | Revenue |
| --- | --- | --- |
| 2025-10-22 | $2.14 | $23.99 B |
| 2025-07-24 | $2.3 | $23.74 B |
| 2025-04-23 | $4.57 | $21.89 B |
| 2024-10-23 | $1.12 | $22.47 B |
| 2025-10-22 | $1.12 | $22.47 B |

EPS (Earning Per Share): generally increasing, with two exceptions.
Revenue: steady growth.

**Revenue and Profitability Analysis**

| Quarter | Revenue | Profit Margin |
| --- | --- | --- |
| 2025-09-30 | $23.99B | 69.56% |
| 2025-06-30 | $23.74B | 67.87% |
| 2025-03-31 | $21.89B | 66.40% |
| 2024-12-31 | $22.52B | 68.35% |
| 2024-09-30 | $22.47B | 69.01% |

Revenue: steady growth, profit margin stable.

**Capital and Profitability Analysis**

| Quarter | Equity | ROE |
| --- | --- | --- |
| 2025-09-30 | $79.28B | 6.50% |
| 2025-06-30 | $78.47B | 7.06% |
| 2025-03-31 | $78.11B | 14.08% |
| 2024-12-31 | $71.49B | 4.80% |
| 2024-09-30 | $70.16B | 3.84% |

Equity: increasing, ROE: unstable.

**Comprehensive Analysis (Summary)**

* Stock price divergence from S&P 500: -40.25%
* Recent stock fluctuations: 2.61 (sharp rebound)
* RSI: 58.19, PPO: -0.20, Market Risk Indicator (MRI): 0.80
* Expected Return: -74.90%
* Sharp rebound/decline: yes
* EPS and revenue increasing, with two exceptions
* Revenue and profit margin: stable, with slight increases in profit margin over the last year.
* Equity and ROE: unstable, with increasing equity.

**Disclaimer:** This report is for informational purposes only and does not constitute financial advice. Investment involves risk.